Genomic complexity and AKT dependence in serous ovarian cancer Journal Article


Authors: Hanrahan, A. J.; Schultz, N.; Westfal, M. L.; Sakr, R. A.; Giri, D. D.; Scarperi, S.; Janakiraman, M.; Olvera, N.; Stevens, E. V.; She, Q. B.; Aghajanian, C.; King, T. A.; de Stanchina, E.; Spriggs, D. R.; Heguy, A.; Taylor, B. S.; Sander, C.; Rosen, N.; Levine, D. A.; Solit, D. B.
Article Title: Genomic complexity and AKT dependence in serous ovarian cancer
Abstract: Effective oncoprotein-targeted therapies have not yet been developed for ovarian cancer. To explore the role of phosphatidylinositol 3-kinase (PI3K)/AKT signaling in this disease, we performed a genetic and functional analysis of ovarian cancer cell lines and tumors. PI3K pathway alterations were common in both, but the spectrum of mutational changes differed. Genetic activation of the pathway was necessary, but not sufficient, to confer sensitivity to selective inhibition of AKT and cells with RAS pathway alterations or RB1 loss were resistant to AKT inhibition, whether or not they had coexistent PI3K/AKT pathway activation. Inhibition of AKT1 caused growth arrest in a subset of ovarian cell lines, but not in those with AKT3 expression, which required pan-AKT inhibition. Thus, a subset of ovarian tumors is sensitive to AKT inhibition, but the genetic heterogeneity of the disease suggests that effective treatment with AKT pathway inhibitors will require a detailed molecular analysis of each patient's tumor. SIGNIFICANCE: A subset of ovarian cancers exhibits AKT pathway activation and is sensitive to selective AKT inhibition. Ovarian tumors exhibit significant genetic heterogeneity and thus an individualized approach based on real-time, detailed genomic and proteomic characterization of individual tumors will be required for the successful application of PI3K/AKT pathway inhibitors in this disease. © 2012 American Association for Cancer Research.
Keywords: signal transduction; protein kinase b; genetics; ovarian neoplasms; metabolism; enzymology; pathology; cell line, tumor; xenograft; ovary tumor; tumor cell line; proto-oncogene proteins c-akt; transplantation, heterologous; genomics; cystadenocarcinoma, serous; cystadenocarcinoma
Journal Title: Cancer Discovery
Volume: 2
Issue: 1
ISSN: 2159-8274
Publisher: American Association for Cancer Research  
Date Published: 2012-01-01
Start Page: 57
End Page: 67
Language: English
DOI: 10.1158/2159-8290.cd-11-0170
PROVIDER: scopus
PMCID: PMC3274821
PUBMED: 22328975
DOI/URL:
Notes: --- - "Cited By (since 1996): 1" - "Export Date: 1 October 2012" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Adriana Heguy
    88 Heguy
  2. Neal Rosen
    425 Rosen
  3. David Solit
    779 Solit
  4. Dilip D Giri
    184 Giri
  5. Douglas A Levine
    380 Levine
  6. Tari King
    186 King
  7. Rita Sakr
    61 Sakr
  8. Qing-Bai She
    31 She
  9. David R Spriggs
    325 Spriggs
  10. Narciso Olvera
    73 Olvera
  11. Chris Sander
    210 Sander
  12. Barry Stephen Taylor
    238 Taylor
  13. Nikolaus D Schultz
    487 Schultz